Equities

PW Medtech Group Ltd

PW Medtech Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)1.17
  • Today's Change-0.02 / -1.68%
  • Shares traded1.11m
  • 1 Year change+88.71%
  • Beta0.3571
Data delayed at least 15 minutes, as of Jul 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PW Medtech Group Ltd is a company principally engaged in the research and development (R&D) and sales of medical devices. The Company operates its businesses through three segments. Infusion Set Business segment is mainly engaged in the R&D, manufacturing and sales of advanced infusion set, intravenous cannula products, insulin needles. Blood Purification Business segment is mainly involved in the R&D, manufacturing and sales of hemodialysis and blood purification medical devices. Regenerative Medical Biomaterials Business segment is mainly involved in the R&D and manufacturing of animal-derived tissue regenerative medical biomaterials and human tissue repair alternative product. The Company mainly operates its businesses in the domestic market.

  • Revenue in HKD (TTM)728.80m
  • Net income in HKD165.37m
  • Incorporated2011
  • Employees1.24k
  • Location
    PW Medtech Group LtdLevel 54Hopewell Centre, 183 Queen's Road EastBEIJING 00000ChinaCHN
  • Phone+86 1 084783617
  • Fax+86 1 084783657
  • Websitehttps://www.pwmedtech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ClouDr Group Ltd3.98bn-348.77m968.61m1.52k--0.4488--0.2431-0.6447-0.64477.373.681.285.484.742,617,744.00-11.33---17.13--24.64---8.87--1.58-29.150.1314--23.51--80.87------
Ziyuanyuan Holdings Group Ltd537.58m15.72m1.22bn184.0072.003.3640.032.260.03930.03931.340.84330.81844.543.022,921,627.002.282.613.673.7124.69--2.786.131.752.340.31354.9653.4152.48-7.90-2.9897.56--
Beijing Airdoc Technology Co Ltd220.19m-143.08m1.31bn339.00--0.7885--5.95-1.38-1.382.1316.060.11912.262.84649,540.60-8.51---9.03--61.35---71.41--11.26--0.006--79.46--26.37------
Sisram Medical Ltd2.80bn245.89m1.41bn1.08k5.750.40063.840.50430.52480.52485.997.540.61471.804.392,597,016.005.635.946.706.8861.1057.669.1610.582.0013.960.086928.791.3618.48-21.597.6146.589.64
IVD Medical Holding Ltd3.33bn257.11m1.45bn803.004.680.33394.880.43390.19020.19022.472.670.67882.785.624,152,108.005.215.186.866.6721.7520.757.687.531.567.530.0923--12.3549.4913.4118.1519.77--
MicroTech Medical Hangzhou Co Ltd273.38m-134.96m1.50bn760.00--0.685--5.50-0.3171-0.31710.64225.230.11372.354.13359,707.80-5.62---5.85--49.13---49.37--21.22--0.00008--45.92---256.75------
Jenscare Scientific Co Ltd0.00-401.32m1.55bn376.00--1.17-----0.962-0.9620.003.190.00----0.00-27.49---28.61----------19.20--0.0347------15.38------
Gaush Meditech Ltd1.52bn187.33m1.66bn869.008.850.91356.171.091.271.2710.2612.260.50572.348.851,746,994.006.22--8.35--49.18--12.30--1.195.900.2814--12.16--149.63------
Peijia Medical Ltd476.23m-423.76m1.75bn1.04k--0.7139--3.68-0.624-0.6240.70113.610.14730.777337.52457,911.70-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75--106.68--
PW Medtech Group Ltd728.80m165.37m1.83bn1.24k11.080.41955.582.510.10560.10560.46552.790.13312.199.21585,854.604.047.234.918.0956.4258.1330.3785.3812.70--0.00024.1125.7516.7844.465.94-7.92--
MicroPort CardioFlow Medtech Corp362.97m-509.06m1.83bn592.00--0.7274--5.05-0.2154-0.21540.15361.040.12052.783.67613,123.30-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Acotec Scientific Holdings Ltd511.55m15.64m1.96bn638.00120.541.4029.963.840.0520.0521.704.470.31360.72133.44801,808.800.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Venus MedTech HangZhou Inc530.47m-759.75m2.48bn865.00--0.7861--4.67-1.74-1.741.217.150.10140.94021.65613,264.20-15.04-13.20-17.41-14.9779.2179.51-148.37-152.831.86-8.780.2206--20.8933.6233.46--58.20--
Data as of Jul 26 2024. Currency figures normalised to PW Medtech Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.80%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 202482.71m5.28%
Dimensional Fund Advisors LPas of 30 Apr 20247.86m0.50%
Dimensional Fund Advisors Ltd.as of 31 May 2024270.43k0.02%
DFA Australia Ltd.as of 30 Apr 202434.50k0.00%
American Century Investment Management, Inc.as of 31 May 20247.00k0.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.